ISCO’s Phase 1 Trial Testing Neural Stem Cell Therapy Completes Patient Enrollment

ISCO’s Phase 1 Trial Testing Neural Stem Cell Therapy Completes Patient Enrollment
Patient enrollment and dosing is now complete for International Stem Cell Corporation’s (ISCO) Phase 1 trial testing its ISC-hpNSC neural stem cells — a cellular therapy that offers a new approach for treating Parkinson’s disease. “We are excited to announce the completion of enrollment of the world’s first approved human pluripotent stem cell-based clinical trial for the treatment of Parkinson’s disease. This ... read more
Source: Parkinson’s News TodayPublished on 2019-04-30By Catarina Silva